“We’re building a strong scientific base for KSM-66 as a clinically-tested adaptogen,” said Ixoreal Biomed director Kartikeya Baldwa.
Ixoreal Biomed (Hyderabad, India) plans to increase North American demand for ashwagandha (Withania somnifera) by increasing the supporting science behind its KSM-66 advanced-form ashwagandha.
Acknowledging that the North American ashwagandha market is “largely undeveloped,” Ixoreal Biomed says it is starting to publish its studies on KSM-66 on human health factors including energy, infertility, immunity, and longevity. The first of five studies Ixoreal Biomed has conducted is now published in the Indian Journal of Psychiatry. It is a human clinical trial on 64 adults under stress conditions.
“We’re building a strong scientific base for KSM-66 as a clinically-tested adaptogen,” said Ixoreal Biomed director Kartikeya Baldwa. “Even though this application had been known through traditional use, very few studies had been conducted prior to our work with KSM-66. We’ve committed our company to be the leader in ashwagandha scientific data.”
KSM-66 is a GRAS-affirmed and Halal-certified ashwagandha ingredient.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.